Renal agenesis medical therapy

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Renal agenesis Microchapters

Home

Patient Information

Overview

Classification

Causes

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Renal agenesis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal agenesis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal agenesis medical therapy

CDC on Renal agenesis medical therapy

Renal agenesis medical therapy in the news

Blogs on Renal agenesis medical therapy

Directions to Hospitals Treating Renal agenesis

Risk calculators and risk factors for Renal agenesis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]

Overview

Patients with unilateral renal agenesis (URA may progress to renal insufficiencyy that may progress to end stage renal disease (ESRD) and therefore may require medical treatment or renal replacement therapy. Early diagnosis of unilateral renal agenesis (URA) and immediate intervention is helpful in controlling the progression to renal insufficiency. The mortality rate of bilateral renal agenesis (BRA) without prenatal therapy with serial amnioinfusion, however, is 100%, however, further studies are required to assess the outcome, risks and benefits of serial amnioinfusion, infancy dialysis and kidney transplantation.

Medical Therapy

Patients with unilateral renal agenesis (URA) have an increased risk for proteinuria, hypertension, and renal insufficiency that may progress to end stage renal disease (ESRD) and may require medical treatment (for example with ACE inhibitors) or renal replacement therapy (such as dialysis).[1][2][3] Early diagnosis of unilateral renal agenesis (URA) and immediate intervention is helpful in controlling the progression to renal insufficiency.[1] The mortality rate of bilateral renal agenesis (BRA) without prenatal therapy with serial amnioinfusion, however is 100%, however, further studies are required to assess the outcome, risks and benefits of this treatment. In addition, further studies are required to assess the outcome of renal replacement with dialysis in infancy and also kidney transplantation.[4]

References

  1. 1.0 1.1 Xu Q, Wu H, Zhou L, Xie J, Zhang W, Yu H; et al. (2019). "The clinical characteristics of Chinese patients with unilateral renal agenesis". Clin Exp Nephrol. 23 (6): 792–798. doi:10.1007/s10157-019-01704-x. PMID 30734167.
  2. Woolf AS, Hillman KA (2007). "Unilateral renal agenesis and the congenital solitary functioning kidney: developmental, genetic and clinical perspectives". BJU Int. 99 (1): 17–21. doi:10.1111/j.1464-410X.2006.06504.x. PMID 16956352.
  3. Argueso LR, Ritchey ML, Boyle ET, Milliner DS, Bergstralh EJ, Kramer SA (1992). "Prognosis of patients with unilateral renal agenesis". Pediatr Nephrol. 6 (5): 412–6. doi:10.1007/BF00873996. PMID 1457321.
  4. Huber C, Shazly SA, Blumenfeld YJ, Jelin E, Ruano R (2019). "Update on the Prenatal Diagnosis and Outcomes of Fetal Bilateral Renal Agenesis". Obstet Gynecol Surv. 74 (5): 298–302. doi:10.1097/OGX.0000000000000670. PMID 31098643.

Template:WH Template:WS